CareDx Cash Flow from Investing Activities 2013-2024 | CDNA
CareDx cash flow from investing activities from 2013 to 2024. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
| CareDx Annual Cash Flow Investing (Millions of US $) |
|
|---|---|
| 2024 | $0 |
| 2023 | $40 |
| 2022 | $-229 |
| 2021 | $48 |
| 2020 | $-100 |
| 2019 | $-23 |
| 2018 | $-8 |
| 2017 | $-6 |
| 2016 | $-21 |
| 2015 | $-1 |
| 2014 | $-1 |
| 2013 | $0 |
| 2012 | $1 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.839B | $0.334B |
| CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of transplant surveillance, such as the use of cell-free DNA (cfDNA) as a biomarker for rejection. CareDx, Inc. is based in Brisbane, California. | |||